PC
SCLN

Palo Capital’s Sciclone Pharmaceuticals Inc SCLN Stock Holding History

Palo Capital’s Portfolio SCLN Stock Details SCLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-20,600
Closed -$227K – 255
2016
Q1 		$227K Buy
+20,600
New +$183K 0.18% 121

Other funds holding SCLN

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Palo Capital's SCLN Position: Q2 2016 in Review

Palo Capital sold out of Sciclone Pharmaceuticals Inc (SCLN) in Q2 2016, closing a stake of 20,600 shares — an estimated $227K sold.

Palo Capital first reported a position in SCLN in Q1 2016 and held it in 1 quarter. The position peaked at $227K in Q1 2016. 151 funds tracked by Wall St. Rank hold SCLN as of Q2 2016.

  • Palo Capital reported no remaining Sciclone Pharmaceuticals Inc position as of Q2 2016 after selling out during the quarter.
  • Palo Capital sold 20,600 Sciclone Pharmaceuticals Inc shares in Q2 2016, an estimated $227K.
  • Palo Capital first reported a position in Sciclone Pharmaceuticals Inc in Q1 2016 and held it in 1 quarter.
  • Palo Capital's Sciclone Pharmaceuticals Inc position peaked at $227K in Q1 2016.
  • 151 funds tracked by Wall St. Rank held Sciclone Pharmaceuticals Inc as of Q2 2016.

Based on Palo Capital's 13F filing for Q2 2016, filed 20 Jul 2016.